To the Editor:
Systemic fluoroquinolones have been known to cause tendinopathy. Since 2008, the US Food and Drug Administration has required a “black-box” warning on all systemic fluoroquinolones because of the risk of tendinopathy and tendon rupture1. Fluoroquinolone-associated tendinopathy symptoms have been documented from as early as 2 hours after the initial exposure to as late as 6 months after discontinuation of therapy2. However, in contrast to systemic fluoroquinolones, no reported cases of tendinopathy have been associated with the use of ophthalmic fluoroquinolones. Further, there is no black-box label for this formulation. We describe a case of tendinopathy following topical ophthalmic fluoroquinolone treatment.
A 56-year-old man with a history of hypothyroidism and cataracts underwent cataract surgery and was administered daily moxifloxacin ophthalmic drops. On day 14 of …
Address correspondence to Dr. Gladue; E-mail: hgladue{at}med.umich.edu